Kali-Extracts Anticipates Explosive Growth in $22 Billion CBD Market Expected to Result From Hemp Farming Legalization Included in $867 Billion Farm Bill
DALLAS, December 13, 2018 /PRNewswire/ --
Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced that the company anticipates explosive growth to result from the legalization of hemp farming included in the 2018 Farm Act. Yesterday, Congress passed the $867 billion farm bill that includes the legalization of hemp farming and President Trump is expected to soon sign the bill into law. A report from the Brightfield Group projects that the hemp-derived CBD market will rapidly expand from about $591 million this year to $22 billion by 2022. Kali-Extracts recently acquired a patented cannabis extraction process validated by research from major medical research institutions. In anticipation of hemp farming being legalized in the farm bill, Kali-Extracts has already been sought out and engaged to begin producing custom hemp-derived CBD extracts. Kali-Extracts recently announced a $300,000 contract weeks after acquiring the patented cannabis extraction process.
"Kali-Extracts has initiated a program to construct mobile hemp-derived CBD extraction labs to be deployed to hemp farms across America," said incoming Kali-Extracts CEO Fred Ferri. "Our extraction process has been proven in multiple research initiatives. Some doctors working with our process have indicated our extracts are superior to those of GW Pharmaceuticals. I believe Kali-Extracts will be both the biggest and the best producer of hemp derived CBD extracts in America."
For more information visit:http://www.kali-extracts.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE Kali, Inc.
Company Codes: OTC-PINK:KALY, OTC-QB:KALY, OTC-QX:KALY, OtherOTC:KALY